MIMEDX Appoints Ricci S. Whitlow as Chief Operating Officer
03 Janeiro 2023 - 10:00AM
MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a
pioneer and leader in placental biologics, today announced that it
has appointed Ricci S. Whitlow as Chief Operating Officer, a role
that will lead the efforts of the Company’s manufacturing, supply
chain, procurement, quality, and regulatory functions. Ms. Whitlow
joins MIMEDX from Catalent, where she most recently served as
President, Clinical Supply Services.
“We are happy to begin 2023 with the addition of
Ricci Whitlow to the MIMEDX leadership team,” stated Todd Newton,
MIMEDX interim Chief Executive Officer. “The future of
placental-based biomaterial products and innovation will
increasingly migrate from the current Human Cells, Tissues and
Cellular and Tissue-Based Products (HCT/P’s) regulatory landscape
to either the device or biologics regulatory pathways. We also see
greater operational complexity in the future as requirements
migrate from Good Tissue Practices (GTPs) to current Good
Manufacturing Practices (cGMPs). As our growth goals depend on our
ability to manage these changes, we identified the need for a
talented and capable operational leader with a unique span of
scientific, technology, process and people-leadership expertise. We
believe Ricci is this leader.”
“I am excited to be joining the MIMEDX team
during this important period in the Company’s history,” stated Ms.
Whitlow. “With MIMEDX’s portfolio of best-in-class products and its
rich product pipeline, the opportunity for our products to help a
variety of patients in a variety of ways is truly remarkable.
MIMEDX’s lifeblood begins with precious birth tissue and combines
with decades of expertise and knowhow to make products that
clinicians and a growing number of patients rely upon. I look
forward to working with my colleagues here to grow our operations
and tackle the large and growing market opportunities we have in
front of us, both today and in the future.”
“This role is absolutely critical to our
long-term success,” continued Mr. Newton. “I look forward to
working with Ricci to continue to bring products to market and
fulfill our mission of leveraging our placental biologics
technology to help address large and growing unmet needs in
medicine.”
Prior to her role at Catalent, Ms. Whitlow’s
extensive career has included leadership roles at a number of
MedTech companies, including Optinose, LifeCell, Kinetic Concepts
and Johnson & Johnson. Ms. Whitlow received her B.S. in
Industrial Engineering from Texas A&M University and her M.B.A.
from the NYU/LSE/HEC TRIUM program.
About MIMEDXMIMEDX is a pioneer
and leader in placental biologics, developing and distributing
placental tissue allografts to help address unmet clinical needs in
multiple sectors of healthcare, including the Advanced Wound Care
market as well as in surgical recovery settings. MIMEDX is also
focused on advancing a promising late-stage pipeline opportunity
targeted at decreasing pain and improving function for patients
with knee osteoarthritis. Our products are derived from human
placental tissues and processed using our proprietary methods,
including the Company’s own PURION® process. We employ Current Good
Tissue Practices, Current Good Manufacturing Practices, and
terminal sterilization to produce our allografts. MIMEDX has
supplied over two million allografts, through both direct and
consignment shipments. For additional information, please visit
www.mimedx.com.
Contact:Matt NotarianniInvestor
Relations470-304-7291mnotarianni@mimedx.com
MiMedx (NASDAQ:MDXG)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
MiMedx (NASDAQ:MDXG)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024